Iradimed Corp is a medical device company that focuses on developing innovative solutions for the healthcare industry, particularly in the field of MRI-compatible anesthesia systems. The company designs and manufactures specialized equipment that enhances the safety and efficiency of medical procedures involving magnetic resonance imaging, thereby improving patient care and outcomes. By combining advanced technology with user-friendly interfaces, Iradimed aims to provide healthcare professionals with tools that streamline workflows and enhance overall clinical efficacy in settings where traditional equipment may pose risks or limitations. Read More
ORLANDO, Fla., Aug. 26, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in innovative medical devices for Magnetic Resonance Imaging (“MRI”) compatible patient monitoring and infusion systems, today announced that it will participate in the Wells Fargo 2025 Healthcare Conference, held September 3-5, 2025, in Boston, Massachusetts.
IRADIMED CORP (IRMD) reported record Q2 2025 earnings, beating estimates with $20.4M revenue and $0.49 EPS. Shares surged 6.27% pre-market as the company raised full-year guidance.
ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
IRADIMED CORP (NASDAQ:IRMD) is a financially strong, debt-free company with high profitability and growth potential, making it a compelling choice for quality investors.
IRadimed Corp (NASDAQ:IRMD) is a debt-free, high-ROIC medical device company with strong profitability and cash flow, making it a candidate for quality investors.
WINTER SPRINGS, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- Iradimed Corporation (NASDAQ: IRMD), a global leader in innovative medical devices for MRI environments, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next-generation MRidium® 3870 IV Infusion Pump System. This advanced, MRI-compatible infusion pump extends Iradimed’s unique position as the world’s only supplier of non-magnetic MRI infusion pump devices, established with our first-generation device in 2005.
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025". The corrected release follows:
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.
WINTER SPRINGS, Fla., March 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) today announced that it will participate in the 37th Annual Roth Conference.
WINTER SPRINGS, Fla., Feb. 13, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three months and year ended December 31, 2024. The Company is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the Company is the only known provider of a (i) non-magnetic intravenous (“IV”) infusion pump system and (ii) a non-magnetic patient vital signs monitoring system that are each designed for use during MRI procedures.
WINTER SPRINGS, Fla., Jan. 30, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 fourth quarter financial results before the market opens on Thursday, February 13, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
WINTER SPRINGS, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD), a leader in developing innovative Magnetic Resonance Imaging compatible medical devices, today reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2024.
WINTER SPRINGS, Fla., Dec. 19, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (“MRI”) compatible medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system announced today that Roger Susi, Chief Executive Officer and Jack Glenn, Chief Financial Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference.
